Clinical and histological findings of palmoplantar pustulosis (PPP). (A) Multiple pustules and pustule-vesicles with ill-circumscribed erythemas on the right palm before secukinumab treatment; (B) A ...

New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent ...

BTIG raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $81 from $71 and keeps a Buy rating on the shares. The firm ...

The clinical program for sonelokimab now includes patients with adolescent hidradenitis suppurativa (HS), palmoplantar pustulosis (PPP) and axial spondyloarthritis (axSpA), in addition to adult ...

palmoplantar pustular psoriasis, pustular erythema multiforme, annular pustular psoriasis, and dermatitis with secondary infection. Differentiating GPP from AGEP is particularly important when making ...

Currently, the treatment of PPP is challenging with ... which is ongoing for palmo-plantar pustulosis (PPP), a debilitating inflammatory skin condition affecting a significant number of patients.

New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial in palmoplantar ...

The VELA-TEEN trial marks a significant advancement in HS treatment. By prioritizing early intervention, we hope to alter the disease course, reduce tissue destruction, and prevent permanent damage.” ...

New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial in palmoplantar ...